The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia

British Journal of Haematology

Volumn 111, Issue 3, 2000, Pages 943-953

  Li, Junzhi ^a   Xia, Yuping ^a   Kuter, David J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Division of Hematology Oncology   (United States)

Author keywords

c mpl; Essential thrombocythaemia; Myeloproliferative disorders; Platelets; Thrombopoietin

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; NUCLEIC ACID; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ADULT; AGED; ARTICLE; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BINDING; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; RECEPTORS, CYTOKINE; RECEPTORS, THROMBOPOIETIN; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOPOIETIN;

EID: 0034490533     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02430.x     Document Type: Article

References (54)

1. Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients
2. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl
3. Human platelets display high-affinity receptors for thrombopoietin
4. Evidence for a platelet membrane defect in the myeloproliferative syndromes
5. Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders
6. Platelet resistance to prostaglandin D2 in patients with myeloproliferative disorders
7. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand
8. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin
9. Clonality analysis of hematopoiesis and thrombopoietin levels in patients with essential thrombocythemia
10. Familial essential thrombocythemia
11. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
12. Human platelets as a model for the binding and degradation of thrombopoietin
13. The clinical spectrum of thrombocytosis and thrombocythemia
14. A possible role for thrombopoietin and its receptor c-mpl in the pathobiology of essential thrombocythemia
15. Thrombocytopenia in c-mpl-deficient mice
16. Thrombokinetics in man
17. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications
18. Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value
19. Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells
20. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia
21. Essential thrombocythemia: Clinical and laboratory characteristics at presentation
22. Megakaryocyte and erythroid colony formation in essential thrombocythaenua and reactive thrombocytosis: Diagnostic value and correlation to complications
23. Purification and characterization of thrombopoietin
24. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin
25. Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha- adrenergic receptors
26. Study of the thrombopoietin receptor in essential thrombocythemia
27. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene
28. The physiology of platelet production
29. The regulation of platelet production
30. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production
31. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: Binding, internalization, stability and pharmacodynamics
32. Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets
33. Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders
34. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo
35. Essential thrombocythemia in young adults
36. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera
37. Platelet Fc receptor. Increased expression in myeloproliferative disease
38. Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group
39. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment
40. Thrombopoietin levels after chemotherapy and in naturally occurring human diseases
41. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders
42. Expression of c-Mpl and c-Mpl ligand gene in hematopoietic cells of individuals with and without myeloproliferative disorders and leukemia cell lines
43. Bleeding and thrombosis in the myeloproliferative disorders
44. Essential thrombocythemia: A clonal disorder of hematopoietic stem cell
45. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders
46. Primary thrombocythemia
47. Abnormalities of megakaryocytes in myelitis and chronic myeloproliferative diseases
48. Influence of thrombopoietin on platelet activation in myeloproliferative disorders
49. Association of thrombocytopenia with the use of intra-aortic balloon pumps
50. Abnormal platelet function in myeloproliferative disorders
51. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis
52. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia
53. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia